Frequently Asked
Questions
What is the Avantect Pancreatic Cancer Test?
The Avantect Pancreatic Cancer Test is a new cell-free DNA-based blood test that detects epigenomic and genomic signals of cancer from cell-free DNA (cfDNA) circulating in blood. It is performed in ClearNote Health’s CLIA-certified and CAP-accredited laboratory. The test enables early detection of pancreatic cancer in patients with high risk for the disease, such as those aged 50+ who are newly diagnosed (within 36 months) with type 2 diabetes and those with a genetic predisposition and/or family history of pancreatic cancer.
What does the Avantect Pancreatic Cancer Test measure?
The Avantect Pancreatic Cancer Test measures the presence or absence of an abnormal signal in cell-free DNA that is associated with pancreatic cancer.
Who can order the Avantect Pancreatic Cancer Test?
Physicians or other physician-designated healthcare professionals can order the Avantect Pancreatic Cancer Test.
What is the Virtuoso Epigenomic platform?
Virtuoso is a research use only (RUO) platform that provides insights into active biological processes using whole genome epigenomic and genomic features revealed by a novel laboratory workflow and combined using a machine learning algorithm.
Contact Us
Ask our expert support team any questions.
